Karl Kammermeyer Lecture Series

Thursday, January 28 at 3:30 pm to 4:20 pm
Pappajohn Business Building, W151
21 East Market Street, Iowa City, Iowa

Buddy D. Ratner, Ph.D. Director, University of Washington Engineered Biomaterials (UWEB21) Michael L. and Myrna Darland Endowed Chair in Technology Commercialization Professor of Bioengineering and Chemical Engineering University of Washington Reception immediately following in W101 PBB -- Biomaterials : Biocompatibility : Tissue Engineering — A Close Family of Ideas Biomaterials are widely used in medical devices and other biointerface applications. Tissue engineering is an upcoming field that makes much use of biomaterials and should have huge impact on medicine in the near future. This talk will illustrate how new concepts in biocompatibility can unite ideas in the older field of biomaterials and the newer field of tissue engineering. Millions of medical devices made of synthetic or modified natural materials are implanted in humans each year saving millions of lives and improving the quality of life for millions more. These implants trigger a similar reaction, the foreign body reaction (FBR). Biocompatibility, for materials that pass routine cytotoxicity testing, is largely associated with a mild FBR, i.e., a thin, avascular, non-adherent foreign body capsule. The implant is incorporated into a “dead-zone” of acellular scar. The contemporary biomaterials and tissue engineering paradigm would suggest that all synthetic biomaterials and scaffolds (particularly those lacking cellular, biomolecule or biomimetic elements) will give this same fibrotic, avascular healing reaction. In this talk, synthetic biomaterials will be described that readily integrate into tissue and may stimulate spontaneous reconstruction of tissue.   The in vivo results from our group and related results from other groups suggest we are on the cusp of a revolution in healing, biomaterials integration and tissue reconstruction. This biomaterials-driven healing much resembles outcomes seen in tissue engineering. The healing observation challenges the present, widely accepted definition of biocompatibility: “The ability of a material to perform with an appropriate host response in a specific application” (Definitions in Biomaterials, Elsevier, 1987) This definition is accurate, but is it useful given new discoveries relating to the biological reaction to implanted materials? We believe the definition of biocompatibility needs refining and redefinition. As biomaterials are used in more challenging surgical environments, minimizing fibrosis and enhancing regeneration become more important.  Thus, the boundaries between biomaterials and tissue engineering begin to blur. Biography Buddy D. Ratner is Director of the University of Washington Engineered Biomaterials (UWEB21) Engineering Research Center. He holds the Michael L. and Myrna Darland Endowed Chair in Technology Commercialization and is Professor of Bioengineering and Chemical Engineering, University of Washington. Buddy Ratner received his Ph.D. (1972) in polymer chemistry from the Polytechnic Institute of Brooklyn. He has been at the University of Washington since 1972. From 1985-1996, he directed the National ESCA and Surface Analysis Center for Biomedical Problems funded by the National Institutes of Health. In 1996, he assumed the directorship of UWEB (now UWEB21). Ratner is a fellow of the American Institute of Medical and Biological Engineering (AIMBE), the AVS (formerly the American Vacuum Society), the American Association for the Advancement of Science, the Biomedical Engineering Society (BMES), the American Chemical Society (ACS), the International College of Fellows Biomaterials Science and Engineering, ACS POLY and the Tissue Engineering and Regenerative Medicine Society (TERMIS). He is a past president of the Society for Biomaterials. He served as president of AIMBE (2002-2003). In 2003 he was elected President of the Tissue Engineering Society of North America. In 2002, Ratner was elected a member of the National Academy of Engineering (NAE), USA. He served on the National Advisory Council of the National Institute of Bioimaging and Bioengineering (NIBIB), NIH (2009-2013). Ratner has won numerous awards. A partial list includes the Medard W. Welch Award of the American Vacuum Society (2002), Founders Award of the Society for Biomaterials (2004), C. William Hall Award from the Society for Biomaterials (2006), the BMES Pritzker Distinguished Lecturer Award (2008), the Acta Biomaterialia gold medal (2009), the University of Washington Faculty Lecture (2011), the Pierre Galletti Award from the American Institute of Medical and Biological Engineering (2011) and the George Winter Award of the European Society for Biomaterials (2012-2013). In 2014 he received the “2014 Lifetime Inventor and Innovator Award” from the University of Washington. Three honors were received in 2015: Distinguished Service Award, ACS Division of Polymer Chemistry; Langmuir Lecture, American Chemical Society (COLL Division); and Most Cited Paper Award, Annals of Biomedical Engineering. Ratner has authored over 400 scholarly works and has over 30 issued patents. He is on the advisory board of Biointerphases and serves on the editorial boards of ten other journals. He is the lead editor for Biomaterials Science: An Introduction to Materials in Medicine, a textbook that has sold over 35,000 copies. He has supervised the theses of more than 80 graduate students. Buddy Ratner’s professional interests include biomaterials, tissue engineering, polymers, biocompatibility, drug delivery, surface analysis, self-assembly, nanobiotechnology, RF-plasma thin film deposition, technology commercialization and biomaterials education. He has participated in the launch of eight companies based on technologies from his laboratory, and serves as a consultant for numerous other companies.

Contact Info: Katie Schnedler, chemical-engineering@uiowa.edu, 335-1215